1 of 14

The Importance of Rapid Diagnosis For COVID-19 and Influenza A+B

  • Why the Biopanda COVID-19 and Influenza A+B Ag Combo Rapid Test should Be utilised by Healthcare Professionals.

2 of 14

Objectives

  • Explain why rapid diagnosis is crucial for respiratory infections.
  • Review two pathogens: COVID‑19 and Influenza.
  • Highlight the role of the Biopanda Rapid Test.
  • Discuss integration into clinical practice.

3 of 14

Why Accurate Diagnosis Matters

  • Respiratory infections cause high global morbidity and mortality.
  • Overlapping symptoms make clinical diagnosis difficult.
  • Rapid pathogen identification guides appropriate therapy and infection control.
  • Reduces unnecessary antibiotic use and improves patient outcomes.

4 of 14

COVID‑19 (SARS‑CoV‑2)

  • Major global health impact.
  • Symptoms overlap with Influenza and RSV.
  • Rapid identification supports isolation, antiviral treatment, and outbreak control.
  • Co‑infections can complicate management.

5 of 14

Influenza A & B

  • Annual outbreaks with millions of cases.
  • Early diagnosis enables timely antiviral therapy.
  • Rapid differentiation from COVID‑19 avoids unnecessary isolation or testing.
  • Combined detection helps during co‑circulation seasons.

6 of 14

Diagnostic Challenges

Similar symptoms between COVID and Flu.

Co‑infections are common.

Traditional PCR or cultures take longer.

Delays lead to inappropriate therapy and higher transmission risk.

7 of 14

Advantages of Combo Rapid Tests

  • Detect 2 pathogens from a single sample.
  • Provide results in minutes for faster decisions.
  • Improve infection control and clinical efficiency.
  • Support antibiotic stewardship and resource savings.

8 of 14

Biopanda COVID-19 and Influenza A+B Ag Combo Rapid Test.

Detects COVID‑19 and Influenza A+B antigens.

Lateral flow format – simple, fast, and reliable.

Provides actionable results within minutes.

Ideal for clinics, hospitals, and community healthcare settings.

9 of 14

Performance Characteristics

Name

Sensitivity

Specificity

Accuracy

COVID-19

94.1%

99.7%

97.0%

Influenza A

95.0%

99.1%

98.4%

Influenza B

92.9%

99.1%

98.1%

For more clinical validation data please contact us.

10 of 14

Clinical Benefits for Healthcare Professionals

  • Enables faster decision‑making and targeted treatment.
  • Supports infection control and isolation protocols.
  • Reduces unnecessary antibiotic use.
  • Streamlines patient flow and improves outcomes.

11 of 14

Implementation Considerations

  • Use nasal and nasopharyngeal swabs per guidelines.
  • Employ test early in symptom onset.
  • Train staff for accurate use and results interpretation.
  • Integrate into infection control protocols and data systems.

12 of 14

Limitations & Best Practices

  • Lower sensitivity than PCR; confirm negatives if suspicion remains high.
  • Optimal use within diagnostic algorithms.
  • Quality control and staff training are essential.
  • Clinical judgement must guide management.

13 of 14

Summary & Take‑home Messages

  • Rapid diagnosis is essential for optimal respiratory infection management.
  • Biopanda Combo Test detects two key pathogens in one workflow.
  • Improves clinical decisions, infection control, and antibiotic stewardship.
  • Valuable tool for modern healthcare professionals.

14 of 14

Contact Details:

Email: info@biopanda.co.uk

Telephone: + 44 (0) 28 95438774

Website: www.biopanda.co.uk

Address: Biopanda Reagents Ltd, Unit 14 Carrowreagh Business Park, Carrowreagh Road, Dundonald, Belfast, BT16 1QQ, Northern Ireland, United Kingdom

​

Ordering information:

Product Name: COVID-19 and Influenza A+B Ag Combo Rapid Test

Catalogue No.: RAPG-RSPV-002

Kit Size: 20 tests